Skye Bioscience Funds Operations and Clinical Trials Through 2026

Skye Bioscience (SKYE) has released an update.

The Company plans to use the net proceeds from the Private Placement to fund operations into early 2026, which includes several clinical trials: a Phase 2 for nimacimab in obesity, a Phase 2a and 2b for SBI-100 Ophthalmic Emulsion in glaucoma and ocular hypertension, as well as ongoing R&D and general corporate needs. An upcoming Phase 2 trial will test nimacimab, a GLP-1R agonist, their combination, and a placebo on 200 obese patients to assess weight change and various secondary health metrics. The trial’s design is pending finalization and FDA input.

For further insights into SKYE stock, check out TipRanks’ Stock Analysis page.